甘精、地特与人胰岛素对3T3-L1脂肪细胞脂联素mRNA表达的影响
|
摘要
目的:探讨甘精、地特与人胰岛素对3T3-L1脂肪细胞脂联素mRNA表达的影响。
方法:1.体外培养3T3-L1前脂肪细胞,诱导分化成熟后用基础培养基培养24h,以消除分化培养基的影响;接着加入含有1nmol/L、10nmol/L、100nmol/L、1000nmol/L人胰岛素(纯品)、甘精胰岛素(纯品及注射液)、地特胰岛素(注射液)的基础培养基培养24 h,并设立基础培养基组为空白对照组,培养24h,用实时定量反转录-聚合酶链式反应(RT-PCR)法检测脂肪细胞脂联素mRNA水平。
2.统计学处理:数据用均数±标准差( x±s)表示;多组定量资料的比较采用单因素方差分析,两两比较用LSD-t检验或Dunnet's法。P≤0.05认为差异具有统计学意义。
结果:1.不同浓度相同胰岛素对脂联素mRNA表达的影响:不同浓度(1、10、100、1000)nmol/L的各种胰岛素作用于成熟的3T3-L1脂肪细胞24h ,随着胰岛素浓度的增加,脂联素mRNA的表达逐渐降低。胰岛素浓度≤10nmol/L时,脂联素表达的降低没有统计学意义(P>0.05);浓度≥100nmol/L时,脂联素的表达明显降低,具有统计学意义(P<0.05),且1000nmol/L胰岛素的抑制作用强于100nmol/L胰岛素。
2.相同浓度不同胰岛素对脂联素mRNA表达影响的比较:1～10nmol/L各组间比较无差别。100nmol/L、1000nmol/L地特胰岛素(注射液)的抑制作用弱于甘精胰岛素(纯品及注射液)及人胰岛素(纯品);甘精胰岛素(纯品及注射液)的抑制作用弱于人胰岛素(纯品);甘精纯品与甘精注射液组相比无差别。
结论: 1.高浓度(100nmol/L、1000nmol/L)甘精、地特、人胰岛素均不同程度地抑制3T3-L1脂肪细胞脂联素mRNA的表达,且呈剂量依赖性。
2.地特胰岛素的抑制作用弱于甘精胰岛素及人胰岛素;甘精胰岛素的抑制作用弱于人胰岛素。
Objective: To investigate the effect of glargine,detemir and human insulin on the expression of adiponectin mRNA in 3T3 - L1 adipocytes.
Methods: 1.3T3-L1 preadipocytes were cultured in vitro until they were differentiated into mature adipocytes,then they were cultured in basal medium for 24 hours to eliminate the influence of differentiation medium,at last they were cultured for 24 hours in basal medium which containing of 1nmol/L,10nmol/L,100nmol/L,1000nmol/L human insulin(powder),insulin glargine(powder and injection) , insulin detemir (injection ) ,and established basal medium group for control group, after 24 hours, the level of adiponectin mRNA in adipocytes were measured by real-time quantitative reverse transcription - polymerase chain reaction (RT - PCR ).
2.Statistics analysis: Values are presented as mean±SE. Many groups of quantitative data were compared by one-way analysis of variance (ANOVA),multiple comparison used LSD-t test or Dunnet's method . A P-value≤0.05 was considered statistically significant.
Results: 1.The effect of different concentrations but same insulins on the expression of adiponectin mRNA:different concentrations (1nmol/L, 10nmol/L, 100nmol/L, 1000nmol/L) of insulins acted on mature 3T3- L1 adipocytes for 24h, along with the increase of insulin concentration,adiponectin mRNA expression reduced gradually.The suppress effects of insulins on adiponectin expression were not significant ( P > 0.05 ) when the concentration≤10nmol/L.When the concentration of insulins was higher than 100nmol/L,the adiponectin expression was significantly suppressed(P<0.05).The inhibition of 1000nmol/L insulins were stronger than 100nmol/L insulins.
2.The comparison of the effects of same concentrations but different insulins on the expression of adiponectin mRNA:there were no differences among groups when the concentration of insulins was 1～10nmol/L. When the concentration of insulins was 100nmol/L, 1000nmol/L,the inhibition of insulin detemir (injection) was weaker than insulin glargine(powder and injection) and human insulin(powder).The inhibition of insulin glargine(powder and injection) was weaker than insulin human(powder). There were no statistical differences between glargine insulin powder and glargine insulin injection.
Conclusion:1. High concentration (100nmol/L,1000nmol/L)glargine,detemir and human insulin all inhibit adiponectin mRNA expression in 3T3 - L1 adipocytes with varing degrees,and in a dose-related manner.
2. The inhibition of insulin detemir is weaker than insulin glargine and insulin human.The inhibition of insulin glargine is weaker than insulin human.
方法:1.体外培养3T3-L1前脂肪细胞,诱导分化成熟后用基础培养基培养24h,以消除分化培养基的影响;接着加入含有1nmol/L、10nmol/L、100nmol/L、1000nmol/L人胰岛素(纯品)、甘精胰岛素(纯品及注射液)、地特胰岛素(注射液)的基础培养基培养24 h,并设立基础培养基组为空白对照组,培养24h,用实时定量反转录-聚合酶链式反应(RT-PCR)法检测脂肪细胞脂联素mRNA水平。
2.统计学处理:数据用均数±标准差( x±s)表示;多组定量资料的比较采用单因素方差分析,两两比较用LSD-t检验或Dunnet's法。P≤0.05认为差异具有统计学意义。
结果:1.不同浓度相同胰岛素对脂联素mRNA表达的影响:不同浓度(1、10、100、1000)nmol/L的各种胰岛素作用于成熟的3T3-L1脂肪细胞24h ,随着胰岛素浓度的增加,脂联素mRNA的表达逐渐降低。胰岛素浓度≤10nmol/L时,脂联素表达的降低没有统计学意义(P>0.05);浓度≥100nmol/L时,脂联素的表达明显降低,具有统计学意义(P<0.05),且1000nmol/L胰岛素的抑制作用强于100nmol/L胰岛素。
2.相同浓度不同胰岛素对脂联素mRNA表达影响的比较:1～10nmol/L各组间比较无差别。100nmol/L、1000nmol/L地特胰岛素(注射液)的抑制作用弱于甘精胰岛素(纯品及注射液)及人胰岛素(纯品);甘精胰岛素(纯品及注射液)的抑制作用弱于人胰岛素(纯品);甘精纯品与甘精注射液组相比无差别。
结论: 1.高浓度(100nmol/L、1000nmol/L)甘精、地特、人胰岛素均不同程度地抑制3T3-L1脂肪细胞脂联素mRNA的表达,且呈剂量依赖性。
2.地特胰岛素的抑制作用弱于甘精胰岛素及人胰岛素;甘精胰岛素的抑制作用弱于人胰岛素。
Objective: To investigate the effect of glargine,detemir and human insulin on the expression of adiponectin mRNA in 3T3 - L1 adipocytes.
Methods: 1.3T3-L1 preadipocytes were cultured in vitro until they were differentiated into mature adipocytes,then they were cultured in basal medium for 24 hours to eliminate the influence of differentiation medium,at last they were cultured for 24 hours in basal medium which containing of 1nmol/L,10nmol/L,100nmol/L,1000nmol/L human insulin(powder),insulin glargine(powder and injection) , insulin detemir (injection ) ,and established basal medium group for control group, after 24 hours, the level of adiponectin mRNA in adipocytes were measured by real-time quantitative reverse transcription - polymerase chain reaction (RT - PCR ).
2.Statistics analysis: Values are presented as mean±SE. Many groups of quantitative data were compared by one-way analysis of variance (ANOVA),multiple comparison used LSD-t test or Dunnet's method . A P-value≤0.05 was considered statistically significant.
Results: 1.The effect of different concentrations but same insulins on the expression of adiponectin mRNA:different concentrations (1nmol/L, 10nmol/L, 100nmol/L, 1000nmol/L) of insulins acted on mature 3T3- L1 adipocytes for 24h, along with the increase of insulin concentration,adiponectin mRNA expression reduced gradually.The suppress effects of insulins on adiponectin expression were not significant ( P > 0.05 ) when the concentration≤10nmol/L.When the concentration of insulins was higher than 100nmol/L,the adiponectin expression was significantly suppressed(P<0.05).The inhibition of 1000nmol/L insulins were stronger than 100nmol/L insulins.
2.The comparison of the effects of same concentrations but different insulins on the expression of adiponectin mRNA:there were no differences among groups when the concentration of insulins was 1～10nmol/L. When the concentration of insulins was 100nmol/L, 1000nmol/L,the inhibition of insulin detemir (injection) was weaker than insulin glargine(powder and injection) and human insulin(powder).The inhibition of insulin glargine(powder and injection) was weaker than insulin human(powder). There were no statistical differences between glargine insulin powder and glargine insulin injection.
Conclusion:1. High concentration (100nmol/L,1000nmol/L)glargine,detemir and human insulin all inhibit adiponectin mRNA expression in 3T3 - L1 adipocytes with varing degrees,and in a dose-related manner.
2. The inhibition of insulin detemir is weaker than insulin glargine and insulin human.The inhibition of insulin glargine is weaker than insulin human.
引文
[1]Rasouli N&Kern PA. Adipocytokines and the metabolic complications of obesity [J]. Clin Endocrinol Metab,2008,93(11): S64–S73.
[2]Eduardo Esteve, Wifredo Ricart, Jose Manuel Fernandez-real.Adipocytokines and insulin resistance .The possible role of lipocalin-2, retinol binding protein-4, and adiponectin [J]. Diabetes Care,2009,32(2): S362 - S367.
[3]Kusminski CM& Scherer PE. The road from discovery to clinic: adiponectin as a biomarker of metabolic status[J]. Clinical Pharmacology & Therapeutics,2009,86(6): 619-625.
[4]Rabe K,Lehrke M,Parhofer KG,et al. Adipokines and insulin resistance[J]. Mol Med, 2008, 14 (11-12): 741 -751.
[5]Li SS,Shin HJ,Ding EL,et al.Adiponectin levels and risk of type 2 diabetes: a systematic review and meta- analysis[J].JAMA, 2009,302(2):179-188.
[6]Noriyuki Ouchi&Kenneth Walsh. A novel role for adiponectin in the regulation of inflammation[J]. Arteriosclerosis, Thrombosis, and Vascular Biology,2008,28:1219-1221.
[7]Yun JE,Sull JW,Lee HY, et al. Serum adiponectin as a useful marker for metabolic syndrome in type 2 diabetic patients[J]. Diabetes Metab Res Rev, 2009,25(3):259-265.
[8]Hotta K,Funahashi T,Bodkin NL,et al.Circulating concentrations of the adipocyte protein adiponectin are decreased in parallelwith reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys [J].Diabetes,2001,50(5):1126-1133.
[9]Lihn AS,Nyholm B,Pedersen SB,et al. Adiponectin expression in adipose tissue is reduced in first- degree relatives of type 2 diabetic patients[J]. Endocrinology and metabolism, 2003,284(2):E443-E448.
[10]Combs TP, Berg AH, Obici S, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30[J]. Clin Invest, 2001, 108 (12): 1875-1881.
[11]Yamauchi T,Kamon J,Waki H,et al. Globular adiponectin protected ob / ob mice form diabetes and ApoE- deficient mice from atherosclerosis[J].Biol Chem, 2003, 278 (4) : 2461 - 2468.
[12]Yoon MJ,Lee GY,Chung JJ,et al.Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase,p38 mitogen-activated protein kinase,and peroxisome proliferator-activated receptorα[J].Diabetes,2006,55(9):2562-2570.
[13]Yamauchi T, Kamon J,Minokoshi Y,et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase[J]. Nature Medicine,2002, 8:1288-1295.
[14]Zhou L,Deepa SS,Etzler JC, et al. Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-dependent protein kinase kinase- dependent pathways[J].Biol Chem,2009,284(33):22426 -22435.
[15]Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease inwhole-body insulin sensitivity in humans[J]. Diabetes,2002, 51 (6): 1884-1888.
[16]Virkamaki A,Ueki K,Kahn CR. Protein–protein interaction in insulin signaling and the molecular mecha- nisms of insulin resistance[J]. Clinical Investigation,1999,103(7): 931–943.
[17]Rosen ED&Spiegelman BM.Adipocytes as regulators of energy balance and glucose homeostasis[J]. Nature,2006, 444(7121):847-853.
[18]Cnop M, Havel PJ, Utzschneider KM,et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex[J]. Diabetologia, 2003, 46(4): 459–469.
[19]Fasshauer M,Klein J,Neumann S,et al.Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes[J].Biochem Biophys Res Commun,2002,290(3): 1084-1089.
[20]Zhang Y,Matheny M,Zolotukhin S,et al. Regulation of adiponectin and leptin gene expression in white and brown adipose tissues: influence of beta3-adrenergic agonists, retinoic acid, leptin and fasting[J].Biochim Biophys Acta, 2002,1584(2-3):115-122.
[21]Fu L,Isobe K,Zeng Q,et al.β-adrenoceptor agonists downregulate adiponectin, but upregulate adiponectin receptor 2 and tumor necrosis factor-αexpression in adipocytes [J]. Pharmacology, 2007,569(1-2): 155- 162.
[22]Horenburg S,Fischer-Posovszky P,Debatin KM,et al. Influence of sex hormones on adiponectin expression in human adipocytes[J] .Horm Metab Res,2008,40(11):779-786.
[23]Meilleur KG,Doumatey A,Huang H, et al. Circulating adiponectin is associated with obesity and serum lipids in West Africans[J].Clinical Endocrinology & Metabolism,2010,95(7): 3517-3521.
[24]Weiss R,Taksali SE,Dufour S,et al.The“obese insulin sensitive”adolescent:importance of adiponectin and lipid partitioning[J].Clin Endocrinol Metab,2005,90(6):3731-3737.
[25]Banga A,Unal R, Tripathi P,et al. Adiponectin translation is increased by the PPARγagonists pioglitazone andω-3 fatty acids[J].Endocrinology and Metabolism,2009,296 (3):E480-E489.
[26]Halleu CM,Takahashi M,Delporte ML,et al.Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue[J].Biochem Biophys Res Commun, 2001, 288(5):1102-1107.
[27]Blumer RM,Van Roomen CP,Meijer AJ,et al.Regulation of adiponectin secretion by insulin and amino acids in 3T3-L1 adipocytes [J]. Metabolism,2008,57(12):1655-1662.
[28]Sun YG,Zan LS,Wang HB,et al.Insulin inhibits the expression of adiponectin and AdipoR2 mRNA in cultured bovine adipocytes[J].Asian-australasian journal of animal sciences, 2009, 22 (10):1429-1436.
[29]Komer A,Wabitsch M,and Bluher M,et al. Adiponectin expression in humans is dependent on diferentiation of adipocytes and down-regulated by humoral serum components[J].Biochem Biophys Res Commun,2005,337(2):540-550.
[30]Xu GQ,Gong DQ,Chu DS,et al.Cloning and tissue expression of the adiponectin gene in geese[J]. Agricultural Biotechnology,2009,6(2):91-96.
[31]Guo LL , Pan Y&Jin HM.Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan[J].Nephrology Dialysis Transplantation,2009,24(6):1876-1883.
[32]Cullen M,Taniguchi, Brice Emanuelli & C.Ronald Kahn.Critical nodes in signalling pathways: insights into insulin action[J].Nature Reviews Molecular Cell Biology,2006,7:85-96.
[33]Mao X,Kikani CK,Riojas RA,et al.APPL1 binds to adiponectin receptors and mediates adiponectin signaling and function[J].Nat Cell Biol,2006,8(5):516-523.
[34]Wang C,Mao X,Wang L, et al. Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1[J].Biol Chem, 2007,282 (11):7991-7996.
[35]Liu BH,Wang YC,Wu SC,et al.Insulin regulates the expression of adiponectin and adiponectin receptors in porcine adipocytes[J].Domestic Animal Endocrinology, 2008, 34: 352 - 359.
[36]Kurtzhals P,Schaffer L,Sorensen A,et al.Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use[J]. Diabetes , 2000, 49(6): 999 -1005.
[37]Weinstein D,Simon M,Yehezkel E,et al. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells[J].Diabetes Metab Res Rev,2009,25(1):41-49.
[1]Rasouli N&Kern PA. Adipocytokines and the metabolic complications of obesity [J]. Clin Endocrinol Metab,2008,93(11): S64–S73.
[2]郗光霞,赵宝珍.脂联素的表达与调控[J].国际内分泌代谢杂志,2009,29:S26-S29.
[3]Rosen ED & Spiegelman BM. Adipocytes as regulators of energy balance and glucose home- ostasis[J].Nature,2006,444(7121):847-853.
[4]Schraw T,Wang ZV,Halberg N,et al.Plasma adiponectin complexes have distinct biochemical characteristics [J]. Endocrinology, 2008, 149(5), 2270-2282.
[5]Lara-Castro C, Luo N , Wallace P,et al.Adiponectin multimeric complexes and the metabolic syndrome trait cluster[J].Diabetes,2006,55:249-259.
[6]Yamauchi T,Kamon J,Waki H,et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis [J]. Biol Chem, 2003,278(4):2461-2468.
[7]Hug C,Wang J,Ahmad NS,et al.T-cadherin is a receptor for hexameric and high- molecular- weight forms of Acrp30/adiponectin[J].Proc Natl Acad Sci USA,2004,101(28):10308-10313.
[8]Civitarese AE,Jenkinson CP,Richardson D,et al. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of type 2 diabetes[J]. Diabetologia,2004,47(5):816-820.
[9]Fasshauer M,Klein J,Neumann S,et al.Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes[J].Biochem Biophys Res Commun,2002,290(3): 1084-1089.
[10]Zhang Y,Matheny M,Zolotukhin S,et al. Regulation of adiponectin and leptin gene expression in white and brown adipose tissues: influence of beta3-adrenergic agonists, retinoic acid, leptin and fasting[J].Biochim Biophys Acta, 2002,1584(2-3):115-122.
[11]Horenburg S,Fischer-Posovszky P,Debatin KM,et al. Influence of sex hormones on adiponectin expression in human adipocytes[J] .Horm Metab Res,2008,40(11):779-786.
[12]Meilleur KG,Doumatey A,Huang H, et al. Circulating adiponectin is associated with obesity and serum lipids in West Africans[J].Clinical Endocrinology & Metabolism,2010,95(7): 3517-3521.
[13]Banga A,Unal R, Tripathi P,et al. Adiponectin translation is increased by the PPARγagonists pioglitazone andω-3 fatty acids[J].Endocrinology and Metabolism,2009,296 (3):E480-E489.
[14]Wang C,Mao X,Wang L, et al.Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase- mediated serine phosphorylation of IRS-1[J].Biological Chemistry,2007,282 (11):7991-7996.
[15]Ryo M,Nakamura T,Kihara S,et al. Adiponectin as a biomarker of the metabolic syndrome[J]. Circulation, 2004, 68(11), 975-981.
[16]Kumada M,Kihara S,Sumitsuji S,et al.Association of hypoadiponectinemia with coronary artery disease in men[J]. Arteriosclerosis, Thrombosis, and Vascular Biology,2003,23,85-89.
[17]Schulze M, Shai I,Rimm E,et al.Adiponectin and future coronary heart disease events among men with type 2 diabetes[J]. Diabetes, 2005, 54, 534-539.
[18]Pischon T, Girman CJ, Hotamisligil GS,et al. Plasma adiponectin levels and risk of myocardial infarction in men[J]. JAMA,2004,291(14):1730-1737.
[19]Jalovaara K,Santaniemi M,Timonen M,et al.Low serum adiponectin level as a predictor of impaired glucose regulation and type 2 diabetes mellitus in a middle-aged Finnish population[J]. Metabolism, 2008,57(8):1130-1134.
[20]Yun JE,Sull JW,Lee HY, et al.Serum adiponectin as a useful marker for metabolic syndrome in type 2 diabetic patients[J]. Diabetes Metab Res Rev, 2009,25(3):259-265.
[21]Li S,Shin HJ,Ding EL,et al.Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis[J].JAMA, 2009,302(2):179-188.
[22]Hotta K,Funahashi T,Bodkin NL,et al.Circulating concentrations of the adipocyte protein adiponectin are decreased in parallelwith reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys [J].Diabetes,2001,50(5):1126-1133.
[23]Pellme F,Smith U,Funahashi T,et al.Circulating adiponectin levels are reduced in nonobese but insulin resistant first-degree relatives of type 2 diabetic patients[J].Diabetes,2003,52(5):1182.
[24] Tokuyama Y, Osawa H, Ishizuka T,et al. Serum resistin level is associated with insulin sensitivity in Japanese patients with type 2 diabetes mellitus[J].Metablism,2007,56(5): 693-698.
[25]Cia-Hin Lau& Sekaran Muniandy. The novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes[EB/OL]. http://precedings.nature.com/documents/4191/version/1,2010-12-21.
[26]Virkamaki A,Ueki K,Kahn CR. Protein–protein interaction in insulin signaling and the molecular mecha- nisms of insulin resistance[J]. Clinical Investigation,1999,103(7): 931–943.
[27]Luo Z,Zhang Y,Li F,et al. Resistin induces insulin resistance by both AMPK-dependent and AMPK-independent mechanisms in HepG2 cells[J]. Endocrine,2009, 36(1):60-69.
[28]Barnes KM & Miner JL. Role of resistin in insulin sensitivity in rodents and humans[J]. Curr Protein Pept Sci, 2009,10:96-107.
[29]Yamauchi T, Kamon J,Minokoshi Y,et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase[J]. Nature Medicine,2002, 8:1288-1295.
[30]Kim SJ, Nian C& McIntosh CH. Resistin is a key mediator of glucose-dependent insulinotropic polypep- tide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes[J].Biol Chem ,2007,282: 34139- 34147.
[31]Zhou L,Deepa SS,Etzler JC, et al. Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-dependent protein kinase kinase- dependent pathways[J].Biol Chem,2009,284(33):22426 -22435.
[32]Kusminski CM& Scherer PE. The road from discovery to clinic:adiponectin as a biomarker of metabolic status[J]. Clinical Pharmacology & Therapeutics,2009,86:592-595.
[33]Patel SD, Rajala MW,Rossetti L,et al.Disulfide-dependent multimeric assembly of resistin familyhormones[J].Science ,2004,304(5674):1154-1158.
[34]Hartman HB,Hu X,Tyler KX,et al.Mechanisms regulating adipocyte expression of resistin[J].Biol Chem,2002,277:19754-19761.
[35]Gable DR,Hurel SJ& Humphries SE. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease[J]. Atherosclerosis, 2006,188(2):231-244 .
[36]Blagoev B,Kratchmaroval,Nielsen MM, et al. Inhibition of adipocyte differentiation by resistin-like molecule alpha. Biochemical characterization of its oligomeric nature[J].Biol Chem,2002,277(44): 42011-42016.
[37]Yoon MJ,Lee GY,Chung JJ,et al.Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase,p38 mitogen-activated protein kinase,and peroxi- some proliferator-activated receptorα[J].Diabetes,2006,55(9):2562-2570.
[2]Eduardo Esteve, Wifredo Ricart, Jose Manuel Fernandez-real.Adipocytokines and insulin resistance .The possible role of lipocalin-2, retinol binding protein-4, and adiponectin [J]. Diabetes Care,2009,32(2): S362 - S367.
[3]Kusminski CM& Scherer PE. The road from discovery to clinic: adiponectin as a biomarker of metabolic status[J]. Clinical Pharmacology & Therapeutics,2009,86(6): 619-625.
[4]Rabe K,Lehrke M,Parhofer KG,et al. Adipokines and insulin resistance[J]. Mol Med, 2008, 14 (11-12): 741 -751.
[5]Li SS,Shin HJ,Ding EL,et al.Adiponectin levels and risk of type 2 diabetes: a systematic review and meta- analysis[J].JAMA, 2009,302(2):179-188.
[6]Noriyuki Ouchi&Kenneth Walsh. A novel role for adiponectin in the regulation of inflammation[J]. Arteriosclerosis, Thrombosis, and Vascular Biology,2008,28:1219-1221.
[7]Yun JE,Sull JW,Lee HY, et al. Serum adiponectin as a useful marker for metabolic syndrome in type 2 diabetic patients[J]. Diabetes Metab Res Rev, 2009,25(3):259-265.
[8]Hotta K,Funahashi T,Bodkin NL,et al.Circulating concentrations of the adipocyte protein adiponectin are decreased in parallelwith reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys [J].Diabetes,2001,50(5):1126-1133.
[9]Lihn AS,Nyholm B,Pedersen SB,et al. Adiponectin expression in adipose tissue is reduced in first- degree relatives of type 2 diabetic patients[J]. Endocrinology and metabolism, 2003,284(2):E443-E448.
[10]Combs TP, Berg AH, Obici S, et al. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30[J]. Clin Invest, 2001, 108 (12): 1875-1881.
[11]Yamauchi T,Kamon J,Waki H,et al. Globular adiponectin protected ob / ob mice form diabetes and ApoE- deficient mice from atherosclerosis[J].Biol Chem, 2003, 278 (4) : 2461 - 2468.
[12]Yoon MJ,Lee GY,Chung JJ,et al.Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase,p38 mitogen-activated protein kinase,and peroxisome proliferator-activated receptorα[J].Diabetes,2006,55(9):2562-2570.
[13]Yamauchi T, Kamon J,Minokoshi Y,et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase[J]. Nature Medicine,2002, 8:1288-1295.
[14]Zhou L,Deepa SS,Etzler JC, et al. Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-dependent protein kinase kinase- dependent pathways[J].Biol Chem,2009,284(33):22426 -22435.
[15]Stefan N, Vozarova B, Funahashi T, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease inwhole-body insulin sensitivity in humans[J]. Diabetes,2002, 51 (6): 1884-1888.
[16]Virkamaki A,Ueki K,Kahn CR. Protein–protein interaction in insulin signaling and the molecular mecha- nisms of insulin resistance[J]. Clinical Investigation,1999,103(7): 931–943.
[17]Rosen ED&Spiegelman BM.Adipocytes as regulators of energy balance and glucose homeostasis[J]. Nature,2006, 444(7121):847-853.
[18]Cnop M, Havel PJ, Utzschneider KM,et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex[J]. Diabetologia, 2003, 46(4): 459–469.
[19]Fasshauer M,Klein J,Neumann S,et al.Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes[J].Biochem Biophys Res Commun,2002,290(3): 1084-1089.
[20]Zhang Y,Matheny M,Zolotukhin S,et al. Regulation of adiponectin and leptin gene expression in white and brown adipose tissues: influence of beta3-adrenergic agonists, retinoic acid, leptin and fasting[J].Biochim Biophys Acta, 2002,1584(2-3):115-122.
[21]Fu L,Isobe K,Zeng Q,et al.β-adrenoceptor agonists downregulate adiponectin, but upregulate adiponectin receptor 2 and tumor necrosis factor-αexpression in adipocytes [J]. Pharmacology, 2007,569(1-2): 155- 162.
[22]Horenburg S,Fischer-Posovszky P,Debatin KM,et al. Influence of sex hormones on adiponectin expression in human adipocytes[J] .Horm Metab Res,2008,40(11):779-786.
[23]Meilleur KG,Doumatey A,Huang H, et al. Circulating adiponectin is associated with obesity and serum lipids in West Africans[J].Clinical Endocrinology & Metabolism,2010,95(7): 3517-3521.
[24]Weiss R,Taksali SE,Dufour S,et al.The“obese insulin sensitive”adolescent:importance of adiponectin and lipid partitioning[J].Clin Endocrinol Metab,2005,90(6):3731-3737.
[25]Banga A,Unal R, Tripathi P,et al. Adiponectin translation is increased by the PPARγagonists pioglitazone andω-3 fatty acids[J].Endocrinology and Metabolism,2009,296 (3):E480-E489.
[26]Halleu CM,Takahashi M,Delporte ML,et al.Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue[J].Biochem Biophys Res Commun, 2001, 288(5):1102-1107.
[27]Blumer RM,Van Roomen CP,Meijer AJ,et al.Regulation of adiponectin secretion by insulin and amino acids in 3T3-L1 adipocytes [J]. Metabolism,2008,57(12):1655-1662.
[28]Sun YG,Zan LS,Wang HB,et al.Insulin inhibits the expression of adiponectin and AdipoR2 mRNA in cultured bovine adipocytes[J].Asian-australasian journal of animal sciences, 2009, 22 (10):1429-1436.
[29]Komer A,Wabitsch M,and Bluher M,et al. Adiponectin expression in humans is dependent on diferentiation of adipocytes and down-regulated by humoral serum components[J].Biochem Biophys Res Commun,2005,337(2):540-550.
[30]Xu GQ,Gong DQ,Chu DS,et al.Cloning and tissue expression of the adiponectin gene in geese[J]. Agricultural Biotechnology,2009,6(2):91-96.
[31]Guo LL , Pan Y&Jin HM.Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan[J].Nephrology Dialysis Transplantation,2009,24(6):1876-1883.
[32]Cullen M,Taniguchi, Brice Emanuelli & C.Ronald Kahn.Critical nodes in signalling pathways: insights into insulin action[J].Nature Reviews Molecular Cell Biology,2006,7:85-96.
[33]Mao X,Kikani CK,Riojas RA,et al.APPL1 binds to adiponectin receptors and mediates adiponectin signaling and function[J].Nat Cell Biol,2006,8(5):516-523.
[34]Wang C,Mao X,Wang L, et al. Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine phosphorylation of IRS-1[J].Biol Chem, 2007,282 (11):7991-7996.
[35]Liu BH,Wang YC,Wu SC,et al.Insulin regulates the expression of adiponectin and adiponectin receptors in porcine adipocytes[J].Domestic Animal Endocrinology, 2008, 34: 352 - 359.
[36]Kurtzhals P,Schaffer L,Sorensen A,et al.Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use[J]. Diabetes , 2000, 49(6): 999 -1005.
[37]Weinstein D,Simon M,Yehezkel E,et al. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells[J].Diabetes Metab Res Rev,2009,25(1):41-49.
[1]Rasouli N&Kern PA. Adipocytokines and the metabolic complications of obesity [J]. Clin Endocrinol Metab,2008,93(11): S64–S73.
[2]郗光霞,赵宝珍.脂联素的表达与调控[J].国际内分泌代谢杂志,2009,29:S26-S29.
[3]Rosen ED & Spiegelman BM. Adipocytes as regulators of energy balance and glucose home- ostasis[J].Nature,2006,444(7121):847-853.
[4]Schraw T,Wang ZV,Halberg N,et al.Plasma adiponectin complexes have distinct biochemical characteristics [J]. Endocrinology, 2008, 149(5), 2270-2282.
[5]Lara-Castro C, Luo N , Wallace P,et al.Adiponectin multimeric complexes and the metabolic syndrome trait cluster[J].Diabetes,2006,55:249-259.
[6]Yamauchi T,Kamon J,Waki H,et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis [J]. Biol Chem, 2003,278(4):2461-2468.
[7]Hug C,Wang J,Ahmad NS,et al.T-cadherin is a receptor for hexameric and high- molecular- weight forms of Acrp30/adiponectin[J].Proc Natl Acad Sci USA,2004,101(28):10308-10313.
[8]Civitarese AE,Jenkinson CP,Richardson D,et al. Adiponectin receptors gene expression and insulin sensitivity in non-diabetic Mexican Americans with or without a family history of type 2 diabetes[J]. Diabetologia,2004,47(5):816-820.
[9]Fasshauer M,Klein J,Neumann S,et al.Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes[J].Biochem Biophys Res Commun,2002,290(3): 1084-1089.
[10]Zhang Y,Matheny M,Zolotukhin S,et al. Regulation of adiponectin and leptin gene expression in white and brown adipose tissues: influence of beta3-adrenergic agonists, retinoic acid, leptin and fasting[J].Biochim Biophys Acta, 2002,1584(2-3):115-122.
[11]Horenburg S,Fischer-Posovszky P,Debatin KM,et al. Influence of sex hormones on adiponectin expression in human adipocytes[J] .Horm Metab Res,2008,40(11):779-786.
[12]Meilleur KG,Doumatey A,Huang H, et al. Circulating adiponectin is associated with obesity and serum lipids in West Africans[J].Clinical Endocrinology & Metabolism,2010,95(7): 3517-3521.
[13]Banga A,Unal R, Tripathi P,et al. Adiponectin translation is increased by the PPARγagonists pioglitazone andω-3 fatty acids[J].Endocrinology and Metabolism,2009,296 (3):E480-E489.
[14]Wang C,Mao X,Wang L, et al.Adiponectin sensitizes insulin signaling by reducing p70 S6 kinase- mediated serine phosphorylation of IRS-1[J].Biological Chemistry,2007,282 (11):7991-7996.
[15]Ryo M,Nakamura T,Kihara S,et al. Adiponectin as a biomarker of the metabolic syndrome[J]. Circulation, 2004, 68(11), 975-981.
[16]Kumada M,Kihara S,Sumitsuji S,et al.Association of hypoadiponectinemia with coronary artery disease in men[J]. Arteriosclerosis, Thrombosis, and Vascular Biology,2003,23,85-89.
[17]Schulze M, Shai I,Rimm E,et al.Adiponectin and future coronary heart disease events among men with type 2 diabetes[J]. Diabetes, 2005, 54, 534-539.
[18]Pischon T, Girman CJ, Hotamisligil GS,et al. Plasma adiponectin levels and risk of myocardial infarction in men[J]. JAMA,2004,291(14):1730-1737.
[19]Jalovaara K,Santaniemi M,Timonen M,et al.Low serum adiponectin level as a predictor of impaired glucose regulation and type 2 diabetes mellitus in a middle-aged Finnish population[J]. Metabolism, 2008,57(8):1130-1134.
[20]Yun JE,Sull JW,Lee HY, et al.Serum adiponectin as a useful marker for metabolic syndrome in type 2 diabetic patients[J]. Diabetes Metab Res Rev, 2009,25(3):259-265.
[21]Li S,Shin HJ,Ding EL,et al.Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis[J].JAMA, 2009,302(2):179-188.
[22]Hotta K,Funahashi T,Bodkin NL,et al.Circulating concentrations of the adipocyte protein adiponectin are decreased in parallelwith reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys [J].Diabetes,2001,50(5):1126-1133.
[23]Pellme F,Smith U,Funahashi T,et al.Circulating adiponectin levels are reduced in nonobese but insulin resistant first-degree relatives of type 2 diabetic patients[J].Diabetes,2003,52(5):1182.
[24] Tokuyama Y, Osawa H, Ishizuka T,et al. Serum resistin level is associated with insulin sensitivity in Japanese patients with type 2 diabetes mellitus[J].Metablism,2007,56(5): 693-698.
[25]Cia-Hin Lau& Sekaran Muniandy. The novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes[EB/OL]. http://precedings.nature.com/documents/4191/version/1,2010-12-21.
[26]Virkamaki A,Ueki K,Kahn CR. Protein–protein interaction in insulin signaling and the molecular mecha- nisms of insulin resistance[J]. Clinical Investigation,1999,103(7): 931–943.
[27]Luo Z,Zhang Y,Li F,et al. Resistin induces insulin resistance by both AMPK-dependent and AMPK-independent mechanisms in HepG2 cells[J]. Endocrine,2009, 36(1):60-69.
[28]Barnes KM & Miner JL. Role of resistin in insulin sensitivity in rodents and humans[J]. Curr Protein Pept Sci, 2009,10:96-107.
[29]Yamauchi T, Kamon J,Minokoshi Y,et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase[J]. Nature Medicine,2002, 8:1288-1295.
[30]Kim SJ, Nian C& McIntosh CH. Resistin is a key mediator of glucose-dependent insulinotropic polypep- tide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes[J].Biol Chem ,2007,282: 34139- 34147.
[31]Zhou L,Deepa SS,Etzler JC, et al. Adiponectin activates AMP-activated protein kinase in muscle cells via APPL1/LKB1-dependent and phospholipase C/Ca2+/Ca2+/calmodulin-dependent protein kinase kinase- dependent pathways[J].Biol Chem,2009,284(33):22426 -22435.
[32]Kusminski CM& Scherer PE. The road from discovery to clinic:adiponectin as a biomarker of metabolic status[J]. Clinical Pharmacology & Therapeutics,2009,86:592-595.
[33]Patel SD, Rajala MW,Rossetti L,et al.Disulfide-dependent multimeric assembly of resistin familyhormones[J].Science ,2004,304(5674):1154-1158.
[34]Hartman HB,Hu X,Tyler KX,et al.Mechanisms regulating adipocyte expression of resistin[J].Biol Chem,2002,277:19754-19761.
[35]Gable DR,Hurel SJ& Humphries SE. Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease[J]. Atherosclerosis, 2006,188(2):231-244 .
[36]Blagoev B,Kratchmaroval,Nielsen MM, et al. Inhibition of adipocyte differentiation by resistin-like molecule alpha. Biochemical characterization of its oligomeric nature[J].Biol Chem,2002,277(44): 42011-42016.
[37]Yoon MJ,Lee GY,Chung JJ,et al.Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase,p38 mitogen-activated protein kinase,and peroxi- some proliferator-activated receptorα[J].Diabetes,2006,55(9):2562-2570.